Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Grifols SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Grifols SA, Medical Devices Deals, 2011 to YTD 2017 10
Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Grifols SA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12
Partnerships 14
Grifols and GigaGen Enter into Research Agreement 14
Grifols Enters into Agreement with MassBiologics 15
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 16
Licensing Agreements 17
Grifols Enters Into Licensing Agreement With Aradigm 17
ThromboGenics Enters into Licensing Agreement with Grifols 18
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 19
Equity Offering 20
Grifols to Invest USD4 Million in AlbaJuna Therapeutics 20
TiGenix Completes Private Placement Of Shares For US$16.2 Million 21
Debt Offering 22
Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 22
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 23
Grifols Completes Public Offering Of 8.25% Bonds For US$1,100 Million 24
Asset Transactions 25
Kedrion Completes Acquisition Of Fractionation Facility And Plasma Collection Centers From Grifols 25
Acquisition 26
Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 26
Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 27
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 28
Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 29
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 30
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 31
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 32
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 33
Grifols Acquires 51% Stake In Araclon Biotech 34
Grifols Completes Acquisition Of Talecris Biotherapeutics 35
Grifols SA – Key Competitors 38
Grifols SA – Key Employees 39
Grifols SA – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 44
Financial Announcements 44
Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million 44
Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 48
May 03, 2017: Bioscience Division sales increase 15% to drive Grifols’ revenue growth by 11% to Euros 1,062 million 54
Feb 28, 2017: Grifols’ revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 58
Nov 08, 2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols’ revenues to EUR 2,952 million 66
Jul 28, 2016: Sales of the Bioscience Division grow by +7.0%, increasing Grifols’ revenues by +2.7% to EUR 1,952 million 70
May 05, 2016: Grifols’ revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the Bioscience Division 76
Feb 29, 2016: Grifols’ revenues grow by 17.3% to Euros 3,935 million, and net profit grows by 13.2% reaching Euros 532 million 80
Corporate Communications 87
Apr 17, 2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program 87
Government and Public Interest 88
Jun 24, 2017: Grifols Awards One Million Dollar Grant to Support the Alpha-1 Foundation’s John W. Walsh Research Fund 88
Product News 89
10/18/2016: Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm Inhaled Ciprofloxacins 89
09/22/2017: FDA approves Grifols Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency 90
Jun 22, 2017: Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples 91
01/05/2016: Aradigm to Host Corporate Update Conference Call on January 6 92
Product Approvals 93
Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency 93
Clinical Trials 94
Sep 22, 2016: Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients 94
Other Significant Developments 95
Jun 16, 2016: Grifols confirms that it has voluntarily signed the EFPIA Code of Conduct 95
Mar 08, 2016: Grifols will invest USD 360M to expand its manufacturing capacities for plasma-derived therapies 96
Mar 03, 2016: Grifols: The company doesn´t have any tax litigation in any country where it operates 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99
Grifols SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Grifols SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Grifols SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Grifols SA, Deals By Therapy Area, 2011 to YTD 2017 9
Grifols SA, Medical Devices Deals, 2011 to YTD 2017 10
Grifols SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12
Grifols and GigaGen Enter into Research Agreement 14
Grifols Enters into Agreement with MassBiologics 15
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 16
Grifols Enters Into Licensing Agreement With Aradigm 17
ThromboGenics Enters into Licensing Agreement with Grifols 18
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 19
Grifols to Invest USD4 Million in AlbaJuna Therapeutics 20
TiGenix Completes Private Placement Of Shares For US$16.2 Million 21
Grifols Raises USD1.06 Billion in Public Offering of 3.2% Bonds Due 2025 22
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 23
Grifols Completes Public Offering Of 8.25% Bonds For US$1,100 Million 24
Kedrion Completes Acquisition Of Fractionation Facility And Plasma Collection Centers From Grifols 25
Grifols Acquires 43.96% Stake in GigaGen for USD35 Million 26
Grifols Acquires 49% Stake in Access Biologicals for USD51 Million 27
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 28
Grifols Acquires 47.58% Stake in Alkahest for USD37.5 Million 29
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 30
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 31
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 32
Grifols Acquires 40% Stake In VCN Biosciences, Maker Of Cancer Treatments 33
Grifols Acquires 51% Stake In Araclon Biotech 34
Grifols Completes Acquisition Of Talecris Biotherapeutics 35
Grifols SA, Key Competitors 38
Grifols SA, Key Employees 39
Grifols SA, Other Locations 40
Grifols SA, Subsidiaries 40
